In the past week, KPRX stock has gone down by -16.62%, with a monthly decline of -7.48% and a quarterly plunge of -8.64%. The volatility ratio for the week is 7.39%, and the volatility levels for the last 30 days are 6.96% for Kiora Pharmaceuticals Inc The simple moving average for the past 20 days is -12.67% for KPRX’s stock, with a -15.78% simple moving average for the past 200 days.
Is It Worth Investing in Kiora Pharmaceuticals Inc (NASDAQ: KPRX) Right Now?
KPRX has 36-month beta value of -0.48. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for KPRX is 2.80M, and currently, short sellers hold a 0.62% ratio of that float. The average trading volume of KPRX on February 12, 2025 was 37.55K shares.
KPRX) stock’s latest price update
Kiora Pharmaceuticals Inc (NASDAQ: KPRX) has experienced a decline in its stock price by -9.44 compared to its previous closing price of 3.60. However, the company has seen a fall of -16.62% in its stock price over the last five trading days. newsfilecorp.com reported 2025-02-11 that Encinitas, California–(Newsfile Corp. – February 11, 2025) – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) today announced it received regulatory approval to initiate KLARITY, a Phase 2 clinical trial to investigate KIO-104 in patients with retinal macular edema, a condition where build-up of fluid behind part of the retina can be associated with adverse vision changes. KIO-104 is a potent, locally delivered small molecule being developed as an alternative to steroids or systemic anti-inflammatory drugs, both of which have known shortcomings.
KPRX Trading at -8.78% from the 50-Day Moving Average
After a stumble in the market that brought KPRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.70% of loss for the given period.
Volatility was left at 6.96%, however, over the last 30 days, the volatility rate increased by 7.39%, as shares sank -4.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.46% lower at present.
During the last 5 trading sessions, KPRX fell by -16.62%, which changed the moving average for the period of 200-days by -28.39% in comparison to the 20-day moving average, which settled at $3.73. In addition, Kiora Pharmaceuticals Inc saw -1.21% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KPRX starting from Stengone Carmine N., who purchase 1,250 shares at the price of $3.68 back on Sep 11 ’24. After this action, Stengone Carmine N. now owns 1,250 shares of Kiora Pharmaceuticals Inc, valued at $4,600 using the latest closing price.
Shapiro Aron, the Director of Kiora Pharmaceuticals Inc, purchase 3,000 shares at $3.60 during a trade that took place back on Sep 10 ’24, which means that Shapiro Aron is holding 3,000 shares at $10,800 based on the most recent closing price.
Stock Fundamentals for KPRX
Current profitability levels for the company are sitting at:
- 0.32 for the present operating margin
- 1.0 for the gross margin
The net margin for Kiora Pharmaceuticals Inc stands at 0.34. The total capital return value is set at 0.15. Equity return is now at value 29.11, with 20.40 for asset returns.
Based on Kiora Pharmaceuticals Inc (KPRX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at 113.3. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 140.3.
Currently, EBITDA for the company is -12.35 million with net debt to EBITDA at -3.54. When we switch over and look at the enterprise to sales, we see a ratio of 0.26. The receivables turnover for the company is 9.14for trailing twelve months and the total asset turnover is 0.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.97.
Conclusion
To put it simply, Kiora Pharmaceuticals Inc (KPRX) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
